Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open Label, Single Arm Trial of Alectinib in Combination With Bevacizumab in Untreated and Previously Treated Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) With Positive ALK Driver Mutation

NCT03779191 is registered in ClinicalTrials.gov with Instituto Nacional de Cancerologia de Mexico as lead sponsor.

NCT NCT03779191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03779191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open Label, Single Arm Trial of Alectinib in Combination With Bevacizumab in Untreated and Previously Treated Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) With Positive ALK Driver Mutation
Lead sponsor
Instituto Nacional de Cancerologia de Mexico
Phase
Phase 2
Overall status
Completed
Start date
April 8, 2020
Completion date
October 30, 2022
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene rearrangement positive, non-squamous non-small cell neoplasm of lung